Dossier assessment
Sacubitril/valsartan (heart failure, children and adolescents) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Sacubitril/valsartan (heart failure, children and adolescents) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Sacubitril/valsartan (heart failure, children and adolescents) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Children and adolescents aged 1 year or older with symptomatic chronic heart failure with left ventricular systolic dysfunction
Added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2023-12-07 A G-BA decision was published.
Project details
- Project no.
- A23-56
- Commission
- Commission awarded on 14.06.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Heart and circulation
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2023-09-15.
- DOI
- https://doi.org/10.60584/A23-56_V1.1
Connected Projects
-
Dossier assessment
Sacubitril/valsartan - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Sacubitril/valsartan (heart failure, children and adolescents) – Addendum to Commission A23-56
Status: Commission completed